Alethio Therapeutics Series A (2026)

Summary

Alethio Therapeutics raised $90 million in Series A funding, announced on 2026-11-05. Sofinnova Partners and RA Capital Management co-led. Oxford Science Enterprises, Cancer Research Horizons and the University of Oxford participated.

The company release, BioPharma Dive, the Oxford RDM note, European Biotechnology and the issue agree on the amount, the stage and the co-leads. The release says the funds will advance ATX-011 through Phase 1/2a studies in essential thrombocythaemia up to Phase 3 readiness, and additional MPN programmes toward IND submission.

Investors

Lead

• Sofinnova Partners lead
• RA Capital Management lead

Participating

• Oxford Science Enterprises participant
• Cancer Research Horizons participant
• University of Oxford participant

Sources

Last verified: 2026-11-05

1. https://alethiotherapeutics.com/alethio-therapeutics-raises-90-million-67-million-in-oversubscribed-series-a-financing-to-advance-a-new-generation-of-therapies-for-myeloproliferative-neoplasms/
   Type: company announcement. Accessed 2026-11-05.
   Alethio Therapeutics release, datelined Oxford, United Kingdom, 5 November 2026. Says oversubscribed $90 million (£67 million) Series A co-led by Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises, with support from Cancer Research Horizons and the University of Oxford. Says proceeds will advance ATX-011 through Phase 1/2a studies in essential thrombocythaemia up to Phase 3 readiness, and additional MPN programmes toward IND submission. Says the company is a University of Oxford spin-out founded by Professors Adam Mead and Beth Psaila. Footer contact address lists Sovereign House, Abingdon Science Park.
2. https://www.biopharmadive.com/news/alethio-therapeutics-myeloproliferative-neoplasms-series-a/873775/
   Type: reputable publication. Accessed 2026-11-05.
   BioPharma Dive. Says Alethio Therapeutics announced Nov. 5, 2026 it raised $90 million in Series A financing co-led by Sofinnova Partners and RA Capital Management, backed by Cancer Research Horizons, Oxford Science Enterprises and the University of Oxford. Calls the company headquartered in Abingdon in Oxfordshire, England.
3. https://www.rdm.ox.ac.uk/news/alethio-spin-out-series-a
   Type: reputable publication. Accessed 2026-11-05.
   University of Oxford Radcliffe Department of Medicine news. Says Alethio Therapeutics secured $90 million (£67 million) in oversubscribed Series A financing co-led by Sofinnova Partners and RA Capital, alongside Oxford Science Enterprises, with support from Cancer Research Horizons and the University of Oxford.
4. https://european-biotechnology.com/latest-news/oxford-spinout-alethio-raises-90m-series-a-for-chronic-blood-cancer-trials/
   Type: reputable publication. Accessed 2026-11-05.
   European Biotechnology Magazine. Says University of Oxford spinout Alethio Therapeutics raised $90 million Series A co-led by Sofinnova Partners and RA Capital, alongside Oxford Science Enterprises, with support from Cancer Research Horizons and the University of Oxford.
5. https://buttondown.com/raisetrack/archive/raise-track-update-2026-11-05/
   Type: other verified public source. Accessed 2026-11-05.
   Raise Track Update for 2026-11-05, Section 1. Amount line $90M (Series A). Calls Alethio an Oxford, UK-based biopharmaceutical company. Names Sofinnova Partners, RA Capital, Oxford Science Enterprises, Cancer Research Horizons, and University of Oxford.